Search results for "AGENT"

showing 10 items of 8904 documents

IFN-alpha Stimulates Proliferation and Cytokine Secretion of CD40-Stimulated B Cell Chronic Lymphocytic Leukemia Cells In Vitro

1999

Interferon (IFN)-alpha has a therapeutic effect in several B cell malignancies, including low-grade non-Hodgkin's lymphoma (NHL), multiple myeloma, and hairy cell leukemia, whereas its efficacy in the treatment of B cell chronic lymphocytic leukemia (B-CLL) is rather limited. In the present study, we investigated the effect of IFN-alpha on the biologic functions of B-CLL cells, which were stimulated by cross-linking of the CD40 antigen. In cell samples from 16 B-CLL patients, the addition of IFN-alpha to CD40-stimulated purified B-CLL cells caused a significant increase in [3H]thymidine uptake (p < 0.003). In B-CLL cells maximally activated by CD40 cross-linking and interleukin-2 (IL-2)/IL-…

medicine.medical_specialtyAdoptive cell transferImmunologyNaive B cellAntineoplastic Agentsimmune system diseaseshemic and lymphatic diseasesVirologyInternal medicineTumor Cells CulturedmedicineHumansHairy cell leukemiaCD40 AntigensCells CulturedB cellCD20B-LymphocytesCD40biologyChemistryInterferon-alphaCell Biologymedicine.diseaseLeukemia Lymphocytic Chronic B-CellStimulation ChemicalClone CellsEndocrinologymedicine.anatomical_structurebiology.proteinCancer researchCytokinesCytokine secretionDrug Screening Assays AntitumorCD5Cell DivisionJournal of Interferon &amp; Cytokine Research
researchProduct

Beta-adrenoceptor-mediated facilitation of endogenous noradrenaline release from rat isolated trachea.

1994

Overflow of endogenous noradrenaline from rat isolated trachea was evoked by electrical field stimulation (3 Hz, 540 pulses) in the presence of yohimbine, desipramine and tyrosine. Isoprenaline 100 nmol/l increased the evoked overflow of noradrenaline by about 65%. This effect was antagonized by propranolol (100 nmol/l) and the beta 2-selective adrenoceptor antagonist ICI 118,551 (100 nmol/l), but not by the beta 1-selective adrenoceptor antagonist CGP 20712 A (100 nmol/l). The beta 2-selective adrenoceptor agonist formoterol (1-100 nmol/l) also facilitated the evoked overflow of noradrenaline, but maximally by only about 25% at 10 nmol/l, i.e. formoterol behaved as a partial agonist at the…

medicine.medical_specialtyAdrenergic beta-AntagonistsIndomethacinAdrenergicPropranololIn Vitro TechniquesPartial agonistNorepinephrine (medication)Rats Sprague-DawleyNorepinephrineAdrenergic AgentsIsoprenalineInternal medicineReceptors Adrenergic betamedicineAnimalsPharmacologyChemistryAntagonistGeneral MedicineElectric StimulationYohimbineRatsTracheaEndocrinologycardiovascular systemFemaleFormoterolmedicine.drugSignal TransductionNaunyn-Schmiedeberg's archives of pharmacology
researchProduct

Current management of atopic dermatitis and interruption of the atopic march.

2003

Treatment of atopic dermatitis requires a comprehensive approach that includes evaluation of potential triggers and education of the patient and family regarding proper avoidance measures. Hydration of the skin and maintenance of an intact skin barrier remain integral to proper management. Although topical corticosteroids have been a mainstay of anti-inflammatory therapy, the newer topical calcineurin inhibitors offer advantages for treatment of this chronic, relapsing disease. Studies aimed at defining optimal combination therapy and early intervention might change the treatment paradigm for atopic dermatitis.

medicine.medical_specialtyAllergyImmunologyCalcineurin InhibitorsAnti-Inflammatory AgentsDiseaseEczema Area and Severity IndexDermatitis AtopicAtopyPrevalenceImmunology and AllergyMedicineHumansSCORADAsthmamedicine.diagnostic_testbusiness.industryCalcineurinDisease ManagementAtopic dermatitismedicine.diseaseSkin CareDermatologyAsthmabody regionsCalcineurinDisease ProgressionDermatologic AgentsbusinessThe Journal of allergy and clinical immunology
researchProduct

Is there a role for antileukotrienes in urticaria?

2006

In vitro and in vivo clinical and experimental data have suggested that leukotrienes play a key role in inflammatory reactions of the skin. Antileukotriene drugs, i.e. leukotriene receptor antagonists and synthesis inhibitors, are a new class of anti-inflammatory drugs that have shown clinical efficacy in the management of asthma. We searched the MedLine database and carried out a manual search on journals specializing in allergy and dermatology for the use of antileukotriene drugs in urticaria. Montelukast might be effective in chronic urticaria associated with aspirin or food additive hypersensitivity or with autoreactivity to intradermal serum injection when taken with an antihistamine b…

medicine.medical_specialtyAllergyLeukotrienesSettore MED/09 - Medicina InternaUrticariamedicine.medical_treatmentDermatologyCold urticariaimmune system diseasesparasitic diseasesmedicineHumansZafirlukastskin and connective tissue diseasesMontelukastAsthmaClinical Trials as TopicAspirinbusiness.industryAnti-Inflammatory Agents Non-SteroidalZileutonmedicine.diseaseDermatologyAntileukotrieneantileukotrieneantileukotrienes; urticariaHistamine H1 AntagonistsLeukotriene AntagonistsAntihistamineDrug Therapy CombinationFood Additivesbusinessmedicine.drugClinical and experimental dermatology
researchProduct

Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management…

2020

Background Experience in Helicobacter pylori eradication treatment of patients allergic to penicillin is very scarce. A triple combination with a PPI, clarithromycin (C), and metronidazole (M) is often prescribed as the first option, although more recently the use of a quadruple therapy with PPI, bismuth (B), tetracycline (T), and M has been recommended. Aim To evaluate the efficacy and safety of first-line and rescue treatments in patients allergic to penicillin in the "European Registry of H pylori management" (Hp-EuReg). Methods A systematic prospective registry of the clinical practice of European gastroenterologists (27 countries, 300 investigators) on the management of H pylori infect…

medicine.medical_specialtyAllergySettore MED/12 - GASTROENTEROLOGIAallergicPenicillinsGastroenterologyHelicobacter InfectionsDrug Hypersensitivity03 medical and health sciences0302 clinical medicineLevofloxacinMetronidazoleClarithromycinInternal medicinebismuthmedicineHumansProspective StudiesRegistriesAdverse effectlevofloxacinbiologyHelicobacter pyloribusiness.industrySettore MED/09 - MEDICINA INTERNAallergic ; allergy ; bismuth ; clarithromycin ; Helicobacter pylori ; levofloxacin ; penicillinGastroenterologyProton Pump InhibitorsGeneral MedicineTetracyclineHelicobacter pyloribiology.organism_classificationmedicine.diseaseallergyclarithromycinAnti-Bacterial Agents3. Good healthPenicillinMetronidazoleRegimenInfectious Diseasespenicillin030220 oncology & carcinogenesisDrug Therapy Combination030211 gastroenterology & hepatologybusinessmedicine.drug
researchProduct

Supportive care of the older cancer patient

2003

Aging is associated with decreased functional reserve of multiple organ systems and with changes in the pharmacokinetics and pharmacodinamics of drugs. Older individuals express enhanced susceptibility to the complications of cytotoxic chemotherapy, especially to myleotoxicity, mucositis, cardiotoxicity and neurotoxicity. The management of older individuals with chemotherapy involves then prevention of these complications. General precautions include proper patient selection, based on the comprehensive geriatric assessment (CGA), dose adjustment for agents that are renally excreted to the patient creatinine clearance and maintenance of hemoglobin levelsor =12 g/dl. Filgrastim and pegfilgras…

medicine.medical_specialtyAnemiaAntineoplastic AgentsColony-Stimulating FactorsNeoplasmsHumansMedicineRisk factorDisease management (health)Intensive care medicineAgedMyelopoiesisStomatitisbusiness.industryIncidence (epidemiology)Age FactorsMouth MucosaDisease ManagementCancerHematologymedicine.diseaseMalnutritionOncologyToxicityDeliriummedicine.symptombusinessCritical Reviews in Oncology/Hematology
researchProduct

Systemic chemotherapy in elderly patients with locally advanced and/or inoperable squamous cell carcinoma of the head and neck: impact of anemia and …

2003

Abstract A review of the incidence and management of anemia in elderly patients with head and neck carcinoma treated with systemic chemotherapy. The role of recombinant human erythropoietin in preventing or correcting chemotherapy-related anemia has been focused. Data concerning the prospective use of recombinant human erythropoietin (rhEpo) in a series of unfit elderly patients (EPs) treated with carboplatin plus 5-fluorouracil. Patients were randomly assigned to receive subcutaneous rhEpo 10,000 U three times per week (TIW) (23 elderly patients) or no treatment (22 control patients). Recombinant hEpo was able to prevent anemia and to reduce transfusional requirements in treated patients a…

medicine.medical_specialtyAnemiamedicine.medical_treatmentAntineoplastic AgentsGastroenterologychemistry.chemical_compoundQuality of lifehemic and lymphatic diseasesInternal medicinemedicineHumansErythropoietinAgedChemotherapybusiness.industryIncidenceIncidence (epidemiology)AnemiaHematologymedicine.diseaseRecombinant ProteinsCarboplatinSurgeryOncologychemistryEpidermoid carcinomaHead and Neck NeoplasmsErythropoietinCarcinoma Squamous CellbusinessComplicationmedicine.drugCritical Reviews in Oncology/Hematology
researchProduct

Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells

2012

Zoledronic acid (ZOL) is the most potent nitrogen-containing bisphosphonate (N-BPs) that strongly binds to bone mineral and acts as a powerful inhibitor of bone resorption, already clinically available for the treatment of patients with osteolytic metastases. Recent data also suggest that ZOL, used in breast cancer, may provide more than just supportive care modifying the course of the disease, though the possible molecular mechanism of action is still unclear. As breast cancer is one of the primary tumours with high propensity to metastasize to the bone, we investigated, for the first time, differential gene expression profile on Michigan Cancer Foundation-7 (MCF-7) breast cancer cells tre…

medicine.medical_specialtyAngiogenesismedicine.medical_treatmentBlotting WesternAngiogenesis InhibitorsAntineoplastic AgentsBreast NeoplasmsBiologyReal-Time Polymerase Chain ReactionZoledronic AcidZOL FN1 TGF-b1 THBS-1 invasion breast cancerBone resorptionThrombospondin 1Transforming Growth Factor beta1breast cancerBreast cancerTGF-β1Internal medicineThrombospondin 1medicineHumansBone ResorptionCell ProliferationMatrigelDiphosphonatesFN1Gene Expression ProfilingImidazolesCancerOriginal ArticlesCell BiologyZOLBisphosphonateMicroarray Analysisinvasionmedicine.diseaseFibronectinsUp-RegulationGene Expression Regulation NeoplasticEndocrinologyZoledronic acidTHBS-1MCF-7 CellsCancer researchMolecular MedicineFemalemedicine.drug
researchProduct

Long-term care of AIDS and non-communicable diseases.

2011

medicine.medical_specialtyAnti-HIV AgentsDeveloping countryMedically Underserved AreaUterine Cervical NeoplasmsZambiaComorbidityHealth servicesAcquired immunodeficiency syndrome (AIDS)Cause of DeathMedicineHumansMass ScreeningIntensive care medicineDeveloping CountriesAcquired Immunodeficiency SyndromeHealth Services Needs and Demandbusiness.industryCancerGeneral Medicinemedicine.diseaseLong-term careFamily medicineChronic DiseaseFeasibility StudiesFemalebusinessLancet (London, England)
researchProduct

Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acqui…

2019

Antifibrinolytics combined with aPCC are not routinely administered to patients with acquired hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and improves the efficacy of therapy, but can increase the risk of severe side effects. Due to these premises it has always raised doubts and perplexities in the clinics. We now report the data of the "FEIBA® on acquired haemophilia A Italian Registry (FAIR Registry)", a retrospective-prospective study that included 56 patients. This is the first study that assessed the clinical response of the combination of aPCC and antifibrinolytic agents in patients with acquired haemophilia A. A total of 101 acute bleeds…

medicine.medical_specialtyAntifibrinolyticmedicine.drug_classHemorrhage030204 cardiovascular system & hematologyHemophilia APremises03 medical and health sciences0302 clinical medicineDrug TherapyThromboembolismAntifibrinolytic agentInternal medicineActivated prothrombin complex concentrateAcquired haemophiliaThromboembolic riskHumansMedicineIn patientRegistries030212 general & internal medicineAcquired haemophilia AHematologybusiness.industryHematologyAcquired haemophilia A; Activated prothrombin complex concentrate; Antifibrinolytics; Thromboembolic risk; Antifibrinolytic Agents; Blood Coagulation Factors; Cardiovascular Diseases; Drug Therapy Combination; Hemophilia A; Hemorrhage; Humans; Registries; ThromboembolismAntifibrinolytic AgentsBlood Coagulation FactorsClinical trialTolerabilityCardiovascular DiseasesCombinationAntifibrinolyticDrug Therapy CombinationAntifibrinolyticsCardiology and Cardiovascular Medicinebusiness
researchProduct